Minutes from CORS BoD meeting, Jan. 7th

Participants:

Board members:
- Sven Frøkjær, Vice-dean, Faculty of Health and Medicines Sciences
- Flemming Madsen, Head of Department of Pharmacy, Faculty of Health and Medicines Sciences
- Karsten Vrangbæk, Centre Director, Centre for Health Economics and Policy
- Robin Evers, Senior Vice President Regulatory Affairs, Novo Nordisk A/S

Chair:
Susanne Kaae, Associate professor, Section for Social and Clinical Pharmacy, CORS SAB member.

Minute taker:
Gitte Borup, MSc Pharm, Administrative assistant, CORS.

Welcome by Sven Frøkjær

CORS News
Susanne Kaae updated the board on the past events and activities carried out in the auspices of CORS.

Note from Robin Evers: The Dutch have the Presidency of the EU for the next year, and will be hosting some events that could be relevant for CORS to participate in. The CORS will stay attentive to what events are most relevant for the center.

News from CORS Scientific Advisory Board
Two PhD-projects have been proposed which has given SAB the opportunity to try the procedure for evaluating projects. This was found quite successful but still needs fine-tuning. Hopefully
following the next SAB meeting at least one PhD-proposal will be approved to go forward to the BoD for final approval. Gitte Borup with support from Anne Marie Shuhaiber Clemensen (Head of the Administration of the Department Pharmacy) will proceed with the initial contracts from the four industrial partners regarding financial support of the projects.

Note from Sven: We have to be aware of creating a coherent scientific environment, and not become too indistinct in our choice of projects.

Robin enquired about masters’ projects within e.g. patient organizations as alterative/supplement to industrial projects.

Regarding the Inaugural Conference planned, it was decided that the conference should be maintained in an academic setting and the Inaugural Lecture for the new CORS professor should open the conference on day 1. Hence, the following reception should also be at a UCPH venue. In order to save costs, it was decided to save the expense of having music during the reception, and external participants who are not directly invited should pay a participant fee. Costs not covered by UCPH and participation fees could be sought covered by the BoD.

Other decisions made:

- Joint meetings with CORS Scientific Advisory Board (SAB) are to take place in the third quarter this year for the new professor to participate.
- The primary purpose of the start-up money donated by Novo Nordisk is for the new professor to have means to initiate research projects and build an international network of cooperators.
- To a question from CORS SAB on PhD-student affiliation, the answer was that the place of employment/enrolment follows the main supervisor. Hence, scientific publications from such PhD student will be affiliated with their primary place of employment and CORS. However, enrollment at the Drug Research Academy for all CORS PhD students should be done if possible when employed at another faculty. (On the matter of the possibility for ‘double-enrolled’ the DRA administrator will put the matter on the next DRA executive committee meeting on Feb. 4th 2016)
- It was decided that Gitte Borup should continue as administrative support until the professor has settled in, and the future administrative requirements have been evaluated.
- In the fall the new professor and Sven Frøkjær are expected to approach new pharmaceutical industries in order to establish new CORS partnerships.